Data and Analytics Sample Clauses

Data and Analytics. ISG Data and Analytics defines and sizes the opportunity for both short- and longer-term sustainable improvements in costs, productivity, quality and other key areas in all supporting processes of global enterprises. Our services help organizations initialize the change through standardization, customer orientation, and the most competitive allocation of resources through delivering full transparency and comparative analysis to support the design of the future state of operational excellence. Services include: Contract Benchmark, Performance Management, Qualitative Assessment and total cost of ownership (TCO) Benchmarking. Digital Strategy and Solutions ISG Strategy helps clients transform their business operations by creating executable strategies and implementing transformative operating models and change programs that achieve desired business outcomes. Services include: Analytics, Digital Backbone, Digital Experience, Digital Strategy, Engineering Solutions and Enterprise Agility. Sourcing Solutions Sourcing Solutions – covering Transaction Services, Transition Services and Financial Analysis – support clients to implement their chosen sourcing strategy via a structured and systematic approach by selecting the best service offering from the most capable service provider at a competitive price. During Transition, ISG helps to plan and execute the transfer of operational delivery responsibility from one party to another. Financial Analysis supports Transaction Services and Renegotiations to optimize the value achieved while mitigating risk. Services include: Document Management Services, IT Financial Management, IT Sourcing Strategy, Mergers and Acquisitions, Operating Model Design and Implementation, Public Sector ERP Software and Integration Services Selection and Project Oversight Services, Transaction Services, ISG FutureSource™ Transaction Methodology, Transition and Transformation, and Blockchain Now™. Network and Software Advisory Services Our Network and Software Advisory Services practice provides a wide range of services to clients. These services include Transformation Services to help clients design, source and successfully move to new network technologies and solutions; Network Sourcing Services to help clients to develop market-leading sourcing strategies to secure maximum savings on network services while developing appropriate contract structure to enable migration to new network services; Audit Services to identify and resolve inaccuracie...
Sample 1Sample 2
AutoNDA by SimpleDocs
Data and Analytics. Training analytics must enable learners to have more effective and engaging learning experiences by leveraging web-based content to inform training needs, through feedback about progress and service delivery performance. Learning analytics will help parole officers to understand diverse learning styles of young people, increase knowledge retention by measuring positive youth development understanding through skill-based demonstration and assessments. Parole Officer will use the data to design more efficient training courses based on specific learning needs.
Sample 1
Data and Analytics. (25 Points): Respondent shall provide description of training and the ability to demonstrate the overall effectiveness of training on the parole officer. Explain how data and analytics will be provided to use as feedback about the progress and ability to provide TJJD employees with feedback about their service delivery performance 3SGF will measure success around identified domains, though pre- and post- tests included on the Xxxxxxx.xx platform. Our program analysis strategies are as follows: 1) Create a baseline understanding of Participant understanding before the training; 2) Determine whether or not there was positive change post training for a. each individual factor measured and b. the domain overall; and 3) Identify any necessary modifications, additions, and/or deletions of the questions and/or domains To make the collection, maintenance, and tracking of the data more efficient, cost effective, and secure, we utilize a professional research tracking tool called QuestionPro. QuestionPro has over
Sample 1
Data and Analytics. Licensor may collect and use performance and use data relating to Licensee’s installation and use of the Licensed Software during the License Term for the purposes of administering the Software License, and improving the Licensed Software and licensing models. Data which Licensor may collect includes, without limitation: (i) license status and validation; (ii) job completion status; (iii) project creation and data flow; (iv) processing workflow steps and amount of intermediate data created; (v) user account activity including the number of active user accounts; (vi) error information; (vii) performance data and hardware utilization; (viii) user experience information. For greater certainty, no proprietary or identifying information of Licensee (e.g., regarding specific targets or ligands) will be collected, and Licensor shall own all such data collected by Licensor.
Sample 1
Data and Analytics. Both Parties, acting reasonably, will share data and analytics generated under and regarding this program to help insure the success of the program, subject to compliance with, and only to the extent permitted by HIPAA and other applicable law and regulation. For clarity, no identifiable data (e.g., names, email, address, IP address or zip code) of any patients may be shared by Pharmacy to Gelesis without such patients’ express prior written consent. Pharmacy will invite patients to acknowledge agreement for personally identifiable data (e.g. email address) to be shared with Gelesis and will do so if the patient does. Pharmacy will house all data and analytics generated by it that include protected health information (PHI) under HIPAA in its database system, in accordance with HIPAA. Examples of the types of data and analytics to be shared by the Parties are set forth in Exhibit B hereto.
Sample 1
Data and Analytics. Emdeon’s Intelligent Healthcare Network, workflow software and large ecosystem of channel partners combines the reach of a national network with the power of software analytics – to deliver targeted and actionable insights to payers, providers, pharmacies and consumers within their normal workflow. The ongoing transformation of the healthcare industry requires all stakeholders to be better informed and make better decisions. Payers need to engage with their plan members in a personalized manner and help them navigate complex clinical and financial decisions. Providers must understand the needs of their patients and be more resourceful in demonstrating value to them. With consumers paying more out of pocket, the experience consumers have with payers and providers will increasingly impact their decisions as to with whom they develop long-term relationships. Our data and analytics solutions are able to use one of the largest and timely sources of healthcare transactional data available, including 8.1 billion transactions, covering $1.2 trillion in claims in 2014. Payers leverage Emdeon’s data to identify and manage risk, stop fraud, waste and abuse and to provide members with better decision-making tools around their healthcare choices. Healthcare systems can benefit from Emdeon’s data and analytics solutions by identifying revenue lost to non-health system providers and inefficient referral patterns that can result in lost revenue for providers.
Sample 1
Data and Analytics. Your Display may offer you the option of opting-in to share data from your Display with Licensor and its affiliated companies. This data is not associated with you, the machine on which your Display is installed (the Machine), or the operator of the Machine. The data includes information about the usage of the Machine (including the Display) and enables Licensor to improve its products and services and create new products and services. For more details about the specific data collected if you choose to opt-in, please refer to the About Usage Data page on your Display. If you choose to opt-in, you reserve the right to opt-out of Display data sharing at any time. However, any data that was shared with Licensor between the date that you opted-in and the date that you opted-out has been received and anonymized by Licensor. Therefore, Licensor cannot delete that data and cannot return that data to you. In addition to the data shared from your Display, Deere may also receive data from the Machine via other Deere products or services, such as JDLink telematics services. The terms governing those products or services, including the collection and usage of data, are covered by the applicable product or service agreements. If you have additional questions about Licensor’s data collection or data analytics processes, please contact Licensor via the Xxxx Deere data privacy page at xxxxx://xxx.xxxxx.xxx/en/privacy-and-data/.
Sample 1
AutoNDA by SimpleDocs
Data and Analytics. The members of Team Toronto will collaborate to share and consolidate data and analysis about Toronto and the region’s industries as well as comparative and competitive cities and key sectors at a global level where appropriate.
Sample 1

Related to Data and Analytics

  • Sampling and Analysis The sampling and analysis of the coal shall be performed by Seller upon loading of the coal, and the results thereof shall be accepted and used as defining the quality and characteristics of the coal under this Agreement and as the Payment Analysis. All analyses shall be made in Seller’s laboratory at Seller’s expense in accordance with ASTM standards where applicable, or industry-accepted standards in other cases. Samples for analyses shall be taken in accordance with ASTM standards or other methods mutually acceptable to both parties. Seller shall transmit its quality analysis to Buyer as soon as possible. Each sample taken by Seller shall be divided into four (4) parts and put into airtight containers, properly labeled and sealed. One (1) part shall be used for analysis by Seller. One (1) part shall be used by Seller as a check sample, if Seller in its sole judgment determines it is necessary. One (1) part shall be retained by Seller until thirty (30) days after the sample is taken (“Disposal Date”), and shall be delivered to Buyer for analysis if Buyer so requests before the Disposal Date. One (1) part (the “Referee Sample”) shall be retained by Seller until the Disposal Date. Buyer, on reasonable notice to Seller, shall have the right to have a representative present to observe the sampling and analyses performed by Seller. Unless Buyer requests an analysis of the Referee Sample before the Disposal Date, Seller’s analysis shall be used to determine the quality of the coal under this Agreement and shall be the Payment Analysis. The Monthly Weighted Averages of specifications referenced in §6.1 shall be based on the individual Shipment analyses. If any dispute arises with regard to the analysis of any sample before the Disposal Date for such sample, the Referee Sample retained by Seller shall be submitted for analysis to an independent commercial testing laboratory (“Independent Lab”) mutually chosen by Buyer and Seller. For each coal quality specification in question, if the analysis of the Independent Lab differs by more than the applicable ASTM reproducibility standards, the Independent Lab results will govern, and the prior analysis shall be disregarded. All testing of the Referee Sample by the Independent Lab shall be at requestor’s expense unless the Independent Lab results differ from the original Payment Analysis for any specification by more than the applicable ASTM reproducibility standards as to that specification. In such case, the cost of the analysis made by the Independent Lab shall be borne by the party who provided the original Payment Analysis.

  • Risk Analysis The Custodian will provide the Fund with a Risk Analysis with respect to Securities Depositories operating in the countries listed in Appendix B. If the Custodian is unable to provide a Risk Analysis with respect to a particular Securities Depository, it will notify the Fund. If a new Securities Depository commences operation in one of the Appendix B countries, the Custodian will provide the Fund with a Risk Analysis in a reasonably practicable time after such Securities Depository becomes operational. If a new country is added to Appendix B, the Custodian will provide the Fund with a Risk Analysis with respect to each Securities Depository in that country within a reasonably practicable time after the addition of the country to Appendix B.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, Registration Statement, the Pricing Disclosure Package or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable laws, rules, regulations and policies of the Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or any committee thereof or of any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; for such studies that have been or are being conducted, the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by foreign government or drug or medical device regulatory agencies, or foreign health care facility Institutional Review Boards; and no investigational new drug application filed by or on behalf of the Company or any of its subsidiaries with the FDA has been terminated or suspended by the FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing studies conducted or proposed to be conducted by or on behalf of the Company or any of its subsidiaries.

  • Quantitative Analysis Quantitative analysts develop and apply financial models designed to enable equity portfolio managers and fundamental analysts to screen potential and current investments, assess relative risk and enhance performance relative to benchmarks and peers. To the extent that such services are to be provided with respect to any Account which is a registered investment company, Categories 3, 4 and 5 above shall be treated as “investment advisory services” for purposes of Section 5(b) of the Agreement.”

  • Special Analyses It is hereby certified that these regulations will not have a significant economic impact on a substantial number of small entities. This certification is based on the fact that it is unlikely that a substantial number of small entities will hold REMIC residual interests. Therefore, a Regulatory Flexibility Analysis under the Regulatory Flexibility Act (5 U.S.C. chapter 6) is not required. It has been determined that this Treasury decision is not a significant regulatory action as defined in Executive Order 12866. Therefore, a regulatory assessment is not required. It also has been determined that sections 553(b) and 553(d) of the Administrative Procedure Act (5 U.S.C. chapter 5) do not apply to these regulations. Drafting Information The principal author of these regulations is Xxxxxxxx Xxxxxxxxxx. However, other personnel from the IRS and Treasury Department participated in their development. List of Subjects 26 CFR Part 1 Income taxes, Reporting and record keeping requirements.

  • XBRL The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

  • Research Reports Distributor acknowledges that Dealer may prepare research reports relating to the Fund that are not to be used for marketing purposes (“Research Reports”). Distributor hereby authorizes Dealer to use the name of the Fund, Distributor and BREDS in Research Reports.

  • Escrow Analysis If applicable, with respect to each Mortgage Loan, the Seller has within the last twelve months (unless such Mortgage was originated within such twelve month period) analyzed the required Escrow Payments for each Mortgage and adjusted the amount of such payments so that, assuming all required payments are timely made, any deficiency will be eliminated on or before the first anniversary of such analysis, or any overage will be refunded to the Mortgagor, in accordance with RESPA and any other applicable law;

  • Product Description The lead products covered by this Settlement Agreement is limited to following Amazon Identification Number (ASIN) B0BBMRLNV9, with the description, "Lesnow 63-37 Tin Lead Rosin Core Solder Wire for Electrical Soldering 0.8mm Soldering Wire Electronics Solder Content Solder Flux 1.8% (0.8mm, 50g)," which was offered for sale by the Settling Entity on xxxxxx.xxx, hereinafter the “Product” or “Products.”

Time is Money Join Law Insider Premium to draft better contracts faster.